On December 28, 2025, a delegation of experts from the Zhejiang Society of Bioinformatics visited Zhejiang Tianyuan Biotechnology Co., Ltd. for an inspection and exchange. Mr. Huang Bisheng, Chairman of the company; Ms. Zhu Youwu, Group Chief Administrative Officer; and Mr. Jiao Mingming, General Manager, warmly received the expert delegation.

      The experts first toured the company’s Science and Technology Exhibition Hall to gain an in-depth understanding of Tianyuan Biotech’s technical strength and development history in the biopharmaceutical field. During the subsequent symposium, Chairman Huang elaborated on the company’s future pipeline planning, outlining its grand blueprint in the biotechnology sector. General Manager Jiao then highlighted the company’s core competencies, including its robust research team, advanced service platforms, and comprehensive quality control system.

      Dr. Liu Guangcheng, Director of the Cell Laboratory, provided an in-depth explanation of the significance of establishing the company's HLA typing bank. He noted that the establishment of this bank not only helps improve the success rate of stem cell transplantation but also provides critical support for personalized medicine. Dr. Chen Junjie, Technical Director of the company, showcased innovative achievements in iPSC (induced Pluripotent Stem Cell) technology and introduced the broad application prospects of iPSC-derived cardiomyocytes in fields such as cell therapy and drug R&D.

      Mr. Chen Ming, President of the Zhejiang Society of Bioinformatics, and Mr. Song Xiaofeng, Executive Vice President of the Jiangsu Society of Bioinformatics, fully affirmed Tianyuan Biotech’s development path in iPSC projects and immune function assessment, offering valuable guidance. They stated that the company’s efforts in technological innovation and translational application have set a model for industry development. Mr. Liao Qi, Deputy Director of the Science and Technology Department at Ningbo University, also expressed his hope to further strengthen ties with Tianyuan Biotech in industry-academia-research cooperation to jointly promote innovative development in biotechnology.

      This visit and exchange activity has deepened mutual understanding between the Zhejiang Society of Bioinformatics and Zhejiang Tianyuan Biotechnology Co., Ltd., laying a solid foundation for collaborative efforts in scientific research and talent cultivation. Tianyuan Biotech will continue to uphold its innovation-driven development philosophy, constantly expanding the application boundaries of biotechnology to contribute to industry advancement and the progress of human health.

      Founded in 2017, Zhejiang Tianyuan Biotechnology Co., Ltd. is a national high-tech enterprise dedicated to cell research and development, manufacturing, operations, and services. The company possesses valuable resource banks, including an HLA Umbilical Cord Matching Bank, an iPS Seed Cell Bank, and a Tumor Cell Bank. It is also a participating unit in formulating the group standard for immune function assessment methods under the National Health Commission (NHC). Furthermore, Tianyuan Biotech has co-established the Joint Laboratory for Metabolic Immune Monitoring with the NHC Research Institute, and serves as key research service platforms such as the Ningbo Storage Center of the National Stem Cell Translational Resource Bank and the Achievement Transformation Center of the NHC Research Institute.